|本期目录/Table of Contents|

[1]祁海啸,缪宏梅,马丽,等.小儿T系急性淋巴细胞白血病的临床预后分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):28-32.[doi:10.3969/j.issn.1672-271X.2023.01.006]
　QI Haixiao,MIAO Hongmei,MA Li,et al.Clinical prognosis of T cell acute lymphoblastic leukemia in children[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(1):28-32.[doi:10.3969/j.issn.1672-271X.2023.01.006]
点击复制

小儿T系急性淋巴细胞白血病的临床预后分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第25卷
期数:
2023年1期
页码:
28-32
栏目:
临床研究
出版日期:
2023-05-10

文章信息/Info

Title:
Clinical prognosis of T cell acute lymphoblastic leukemia in children
作者:
祁海啸; 缪宏梅; 马丽; 蒯文霞; 吴梦颍; 朱从龙
作者单位：223300淮安，南京医科大学附属淮安第一医院儿科（祁海啸、马丽、蒯文霞、吴梦颍、朱从龙）；223400涟水，淮安市涟水县人民医院儿科（缪宏梅）
Author(s):
QI Haixiao1;  MIAO Hongmei2;  MA Li1;  KUAI Wenxia1;  WU Mengying1;  ZHU Conglong1
(1.Department of Pediatrics, Huai′an First Hospital Affiliated to Nanjing Medical University, Huai′an 223300, Jiangsu,China;2.Department of Pediatrics, People′s Hospital of Lianshui County, Lianshui 223400, Jiangsu,China)
关键词:
T系急性淋巴细胞白血病; 小儿; 疾病特点; 预后分析
Keywords:
T cellacute lymphoblastic;  children;  disease characteristics;  prognostic analysis
分类号:
R733.71
DOI:
10.3969/j.issn.1672-271X.2023.01.006
文献标志码:
A
摘要:
目的T系急性淋巴细胞白血病(T-ALL)属于小儿少见且高度恶性的肿瘤性疾病，研究其预后因素及临床特点，为临床带来一定的参考价值。方法回顾性分析南京医科大学附属淮安第一医院收治的54例T-ALL患儿的临床资料，所有患儿均采用上海儿童医学中心SCMC-ALL-2009化疗方案。统计分析研究对象的病史、实验室检查报告、影像学资料、预后情况等。采用Kaplan-Meier方法分析。结果54例患儿的中位生存时间为43.5个月，2个疗程后的完全缓解率为90.74%，3年总生存率和无病生存率分别为81.48%和77.78%，其中24例（44.44%）初诊时伴有纵隔占位。54例中有10例（18.51%）死亡，其中6例（11.11%）死于复发。单因素分析结果显示：年龄、性别、初诊白细胞数、D19是否缓解、D35是否缓解、初诊乳酸脱氢酶、纵隔占位、脾浸润、门冬酰胺酶总量是否足量对3年OS均有统计学意义(P＜0.001)；多因素分析显示年龄（P=0.004）、D35骨髓是否缓解(P＜0.001)、D35 MRD(P＜0.001)、LDH（P=0.019）是影响患者3年总生存率的独立危险因素。结论SCMC-ALL-2009方案对小儿T系急性淋巴细胞白血病的总体疗效较好，少数患儿死亡主要是疾病复发,初诊时乳酸脱氢酶、年龄及D35缓解情况是独立危险因素。
Abstract:
ObjectiveT cell acute lymphoblastic leukemia (T-ALL) is a rare and highly malignant neoplastic disease in children. The study of its prognostic factors and clinical characteristics will bring certain reference value to the clinic.MethodsThe clinical data of 54 children with T-ALL admitted to Huai′an First Hospitalwere retrospectively analyzed. All children were treated with Shanghai Children′s Medical Center - Acute Lymphoblastic Leukemia -2009 (SCMC-ALL-2009) chemotherapy program. The medical history, laboratory examination report, imaging data and prognosis of the subjects were statistically analyzed. Kaplan-Meiermethod was used for survival analysis.ResultsThe median survival time of the 54 children was 43.5 months. The complete remission rate after 2 courses of chemotherapy was 90.74%. And the 3-year overall survival and disease-free survivalrates were 81.48% and 77.78%, respectively, of which 24 (44.44%) had mediastinal mass at the initial diagnosis. Of the 54 cases, 10 cases (18.51%) died, of which 6 cases (11.11%) died of recurrence. The results of univariate analysis showed that age, gender, white blood cell count at the first diagnosis, whether D19 remission, D35 remission, newly diagnosed level of lactate dehydrogenase, mediastinal mass, spleen infiltration, and the sufficient amount of asparaginase were statistically significant for 3-year OS (P＜0.001). Multivariate analysis showed that age（P=0.004）, whether D19 remission(P＜0.001), D35 MRD(P＜0.001) and LDH（P=0.019）were independent risk factors affecting the 3-year overall survival rate.ConclusionSCMC-ALL-2009regimen has a good overall effect on T cell acute lymphoma, and recurrence is the main cause of death in a few children.Lactate dehydrogenase（at initial diagnosis）, age and D35 remission were independent risk factors.

参考文献/References:

[1]高举,陈晓曦. 儿童急性T淋巴细胞白血病诊治进展[J]. 中国小儿血液与肿瘤杂志, 2013，18(4): 148-152.
[2]Hefazi M，Litzow MR. Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia[J]. Curr Hematol Malig Rep, 2018，13(4): 265-274.
[3]常林，陈红兵，朱纯亮，等. 细小病毒B19和儿童急性白血病关系的探讨[J]. 东南国防医药, 2016, 18(2): 171-173.
[4]Karrman K, Johansson B.Pediatric T-cell acute lymphoblastic leukemia[J]. Gene Chromosome Canc, 2017，56(2): 89-116.
[5]Vadillo E, Dorantes-Acosta E, Pelayo R, et al. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies[J]. Blood Rev, 2018, 32(1): 36-51.
[6]张艳兰，赵文理，聂述山，等. 儿童T系急性淋巴细胞白血病的临床特点及预后分析[J]. 中国实验血液学杂志, 2011, 19(6): 1496-1500.
[7]Liu K, Chu J, Dai Y,et al. Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol[J]. Leuk Lymph, 2020, 61(12): 2850-2858.
[8]Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemiabetween 1990 and 2005: A report from the children′s oncology group[J]. J Clin Oncol, 2012, 30(14): 1663-1669.
[9]于亚平. 儿童急性白血病的研究进展[J]. 医学研究生学报,2000,13(z1):50-54.
[10]Reismuller B, Attarbaschi A, Peters C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group[J]. Br J Haematol, 2009, 144(4): 559-570.
[11]Teachey DT，Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia[J]. Lancet Oncol, 2019，20(3): e142-e154.
[12]Pui CH，Evans WE. Treatment of acute lymphoblastic leukemia[J]. N Engl J Med, 2006，354(2): 166-178.
[13]Ghione P, Moskowitz AJ, De Paola N, et al. Novel immunotherapies for t cell lymphoma and leukemia[J]. Curr Hematol Malig Rep, 2018, 13(6): 494-506.
[14]Sanchez-Martin M，Ferrando A. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia[J]. Blood, 2017，129(9): 1124-1133.
[15]Burns MA, Place AE, Stevenson KE, et al. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001[J]. Pediatr Blood Cancer, 2021, 68(1): e28719.
[16]Petit A, Trinquand A, Chevret S, et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia[J]. Blood, 2018, 131(3): 289-300.
[17]Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblasticleukemia[J]. Leuk Lymph, 2018, 59(8): 1797-1806.
[18]Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the children′s oncology group[J]. J Clin Oncol, 2020, 38(17): 1897-1905.
[19]Schore RJ, Devidas M, Bleyer A, et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children′s Oncology Group AALL07P4[J]. Leuk Lymph, 2019, 60(7): 1740-1748.
[20]郭晓红，翟晓文，钱晓文，等. 163例儿童急性淋巴细胞白血病细胞遗传学特征[J]. 中国实验血液学杂志, 2015, 23(2): 312-317.

相似文献/References:

[1]陈新跃,徐 莉,杜 娟,等.检测急性有机磷农药中毒患儿血清NSE的临床意义[J].医学研究与战创伤救治(原医学研究生学报),2011,13(04):310.
[2]张 迪,刘大问,吴彬彬,等.C反应蛋白对小儿呼吸道感染的诊断价值[J].医学研究与战创伤救治(原医学研究生学报),2011,13(04):361.
[3]潘菲,程锐,张祥生.血清维生素D水平与小儿先天性甲状腺功能减低症相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2022,24(2):162.[doi:10.3969/j.issn.1672-271X.2022.02.011]
　PAN Fei,CHENG Rui,ZHANG Xiang-sheng.The correlation of serum vitamin D levels and congenital hypothyroidism in children[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):162.[doi:10.3969/j.issn.1672-271X.2022.02.011]

备注/Memo

备注/Memo:
基金项目：南京医科大学科技发展基金项目（NMUB2018153）
更新日期/Last Update: 2023-04-19